https://www.selleckchem.com/pr....oducts/rituximab.htm
regimen, and is inadequately informed by stroke and bleeding risk scores. In New Zealand, one in seven patients presenting with ACS have AF, a third being new-onset AF. Antithrombotic management is inconsistent, with underutilisation of anticoagulants, particularly the DAT regimen, and is inadequately informed by stroke and bleeding risk scores. New Zealand has among the highest rates of colorectal cancer and inflammatory bowel disease in the world. With the imminent rollout of the National Bowel Screening Programme, we sought to dete
Like
Comment
Share
